The University of Chicago Header Logo

Thinle Chodon

AddressChicago IL 60637
Phone+1 (773) 8346317
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796. PMID: 37463058; PMCID: PMC10690096.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    2. Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Correction to: Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2899. PMID: 35666273; PMCID: PMC9588465.
      Citations:    Fields:    
    3. Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898. PMID: 35460379; PMCID: PMC9588092.
      Citations:    Fields:    Translation:HumansCells
    4. Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402. PMID: 35294258; PMCID: PMC9311231.
      Citations: 18     Fields:    Translation:HumansAnimals
    5. Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10). PMID: 34607898; PMCID: PMC8491420.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    6. Faiena I, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A, Comin-Anduix B. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282. PMID: 32925563.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    7. Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156. PMID: 31221207; PMCID: PMC6587259.
      Citations: 46     Fields:    Translation:HumansCells
    8. Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, Odunsi K. A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7. PMID: 30626427; PMCID: PMC6325755.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    9. Matsueda S, Chodon T, Koya RC. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies. Adv Exp Med Biol. 2019; 1143:217-229. PMID: 31338822.
      Citations: 2     Fields:    Translation:HumansCells
    10. Chodon T, Lugade AA, Battaglia S, Odunsi K. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1025-1039. PMID: 30390758; PMCID: PMC7879480.
      Citations: 5     Fields:    Translation:Humans
    11. Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259. PMID: 29470191; PMCID: PMC5959255.
      Citations: 1     Fields:    Translation:HumansCells
    12. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. PMID: 26787823; PMCID: PMC4775381.
      Citations: 192     Fields:    Translation:HumansCellsCTClinical Trials
    13. Chodon T, Koya RC, Odunsi K. Active Immunotherapy of Cancer. Immunol Invest. 2015; 44(8):817-36. PMID: 26575466.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    14. Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83. PMID: 25038231; PMCID: PMC4167467.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    15. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57. PMID: 24812408; PMCID: PMC4079734.
      Citations: 190     Fields:    Translation:HumansCells
    16. Chodon T, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A, Comin-Anduix B. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374; PMCID: PMC4070853.
      Citations: 113     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    17. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Koya RC, Graeber TG, Robins H, Ribas A, Comin-Anduix B. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32. PMID: 24583799; PMCID: PMC4008652.
      Citations: 200     Fields:    Translation:HumansCells
    18. Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68. PMID: 24795358; PMCID: PMC4010948.
      Citations: 12     Fields:    Translation:HumansCells
    19. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. PMID: 24265155; PMCID: PMC3936420.
      Citations: 493     Fields:    Translation:HumansCells
    20. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. PMID: 24265152; PMCID: PMC3893054.
      Citations: 98     Fields:    Translation:HumansCells
    21. Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829. PMID: 24167550; PMCID: PMC3805549.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    22. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29. PMID: 23519018; PMCID: PMC3716460.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    23. Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J, Birkhäuser FD. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. PMID: 23377663; PMCID: PMC6410717.
      Citations: 13     Fields:    Translation:AnimalsCells
    24. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37. PMID: 22693252; PMCID: PMC3422880.
      Citations: 115     Fields:    Translation:HumansAnimalsCells
    25. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. PMID: 22395615; PMCID: PMC3530385.
      Citations: 318     Fields:    Translation:HumansCells
    26. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011 Jun; 17(6):738-43. PMID: 21602800; PMCID: PMC3681612.
      Citations: 170     Fields:    Translation:HumansCells
    27. Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A, Comin-Anduix B. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8. PMID: 21169256; PMCID: PMC3057460.
      Citations: 74     Fields:    Translation:HumansCells
    28. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7. PMID: 21107323; PMCID: PMC3143360.
      Citations: 1078     Fields:    Translation:HumansCells
    29. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Ribas A, Comin-Anduix B. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct; 33(8):759-68. PMID: 20842061; PMCID: PMC3114626.
      Citations: 17     Fields:    Translation:HumansCells
    30. Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A, Comin-Anduix B. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711. PMID: 20856802; PMCID: PMC2939876.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    31. Koya RC, Mok S, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A, Comin-Anduix B. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14286-91. PMID: 20624956; PMCID: PMC2922609.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    32. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B, UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47. PMID: 20547105; PMCID: PMC2917536.
      Citations: 20     Fields:    Translation:HumansCells
    33. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35. PMID: 19457253; PMCID: PMC2697137.
      Citations: 76     Fields:    Translation:HumansCellsCTClinical Trials
    34. Funayama E, Chodon T, Oyama A, Sugihara T. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol. 2003 Dec; 121(6):1326-31. PMID: 14675177.
      Citations: 30     Fields:    Translation:HumansCells
    35. Furukawa H, Fujita H, Kokubu I, Yamamoto Y, Sasaki S, Chodon T, Okubo Y, Sugihara T, Kuzumaki N, Furukawa H, Fujita H, Kokubu I, Yamamoto Y, Sasaki S, Chodon T, Okubo Y, Sugihara T, Kuzumaki N. Identification of a novel gelsolin truncate in the vertical and metastatic phase malignant melanomas. Melanoma Res. 2002 Dec; 12(6):523-8. PMID: 12459641.
      Citations: 2     Fields:    Translation:HumansCells
    36. Chodon T, Sugihara T, Igawa HH, Funayama E, Furukawa H. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol. 2000 Nov; 157(5):1661-9. PMID: 11073825; PMCID: PMC1885731.
      Citations: 20     Fields:    Translation:HumansCells
    Chodon's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (220)
    Co-Authors (3)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors